Published in Anticancer Drugs on August 01, 1997
Development of macromolecular prodrug for rheumatoid arthritis. Adv Drug Deliv Rev (2012) 1.07
An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob Agents Chemother (2009) 1.04
Albumin binding ligands and albumin conjugate uptake by cancer cells. Diabetol Metab Syndr (2011) 0.85
Albumin-based drug delivery: harnessing nature to cure disease. Mol Cell Ther (2016) 0.82
A platform for efficient, thiol-stable conjugation to albumin's native single accessible cysteine. Org Biomol Chem (2015) 0.78
Albumin-based nanoparticles as magnetic resonance contrast agents: I. Concept, first syntheses and characterisation. Histochem Cell Biol (2010) 0.78
Establishment and characterization of monoclonal antibodies against an octahedral gallium chelate suitable for immunoscintigraphy with PET. J Nucl Med (1992) 1.99
Plasma protein (albumin) catabolism by the tumor itself--implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol (1997) 1.60
Inflammatory cytokines in subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. J Neurol Neurosurg Psychiatry (2001) 1.53
X-ray Monochromator with 2 x 10(8) Energy Resolution. J Synchrotron Radiat (1996) 1.44
Gallium-68 chelate imaging of human colon carcinoma xenografts pretargeted with bispecific anti-CD44V6/anti-gallium chelate antibodies. J Nucl Med (1998) 1.43
The soft x-ray instrument for materials studies at the linac coherent light source x-ray free-electron laser. Rev Sci Instrum (2012) 1.36
First outbreak of Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in Germany. Eur J Clin Microbiol Infect Dis (2010) 1.29
Coherence properties of individual femtosecond pulses of an x-ray free-electron laser. Phys Rev Lett (2011) 1.26
Nanofocusing of hard X-ray free electron laser pulses using diamond based Fresnel zone plates. Sci Rep (2011) 1.16
Radioiodination of proteins and lipoproteins using N-bromosuccinimide as oxidizing agent. Anal Biochem (1988) 1.16
Pathophysiology, clinical manifestations and therapy of consumption-coagulopathy ("Verbrauchskoagulopathie"). Am J Cardiol (1967) 1.15
Formation of a new dynamical mode in -uranium observed by inelastic x-ray and neutron scattering. Phys Rev Lett (2006) 1.05
[Experimental bone scintigraphy in animals]. Nucl Med (Stuttg) (1970) 1.04
Endothelin-1 in subarachnoid hemorrhage: An acute-phase reactant produced by cerebrospinal fluid leukocytes. Stroke (2000) 1.02
Design of compounds having enhanced tumour uptake, using serum albumin as a carrier--Part II. In vivo studies. Int J Rad Appl Instrum B (1992) 1.02
Simplified cell labelling with indium-111 acetylacetone. Br J Radiol (1979) 1.02
The Fibrin Assay Comparison Trial (FACT): evaluation of 23 quantitative D-dimer assays as basis for the development of D-dimer calibrators. FACT study group. Thromb Haemost (2001) 1.00
Binding of acetylated low density lipoprotein and maleylated bovine serum albumin to the rat liver: one or two receptors? EMBO J (1987) 1.00
Synthesis of positively charged phthalocyanines and their activity in the photodynamic therapy of cancer cells. Photochem Photobiol (1990) 0.99
Characterization of binding sites for acetylated low density lipoprotein in the rat liver in vivo and in vitro. EMBO J (1985) 0.95
Hypophosphatemic rickets with hypercalciuria due to mutation in SLC34A3/NaPi-IIc can be masked by vitamin D deficiency and can be associated with renal calcifications. Exp Clin Endocrinol Diabetes (2008) 0.95
Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group. Haemostasis (1996) 0.94
Analysis of fibrin formation and proteolysis during intravenous administration of ancrod. Blood (2000) 0.94
Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Part I. Int J Rad Appl Instrum B (1990) 0.92
Noninfectious thrombosis of the superior sagittal sinus in a patient with iron deficiency anemia. Stroke (1991) 0.92
Genetic and immunological markers predict titanium implant failure: a retrospective study. Int J Oral Maxillofac Surg (2012) 0.92
Towards noninvasive molecular fluorescence imaging of the human brain. Neurodegener Dis (2008) 0.91
Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res (1990) 0.91
Evaluation of a new selective medium, BD BBL CHROMagar MRSA II, for detection of methicillin-resistant Staphylococcus aureus in different specimens. J Clin Microbiol (2010) 0.90
Observation of phonons with resonant inelastic x-ray scattering. J Phys Condens Matter (2010) 0.89
Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society. Clin Cancer Res (1999) 0.89
[Studies on the alkylating effect of 14C-methylnitrosourea and 1-14C-ethylnitrosurea]. Experientia (1968) 0.89
Hemolysis and blood loss in children with chronic renal failure. Clin Nephrol (1977) 0.87
Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res (1999) 0.87
Binding characteristics of reduced hepatic receptors for acetylated low-density lipoprotein and maleylated bovine serum albumin. Biochem J (1990) 0.87
Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo. Int J Cancer (2001) 0.86
Albumin-based drug carriers: comparison between serum albumins of different species on pharmacokinetics and tumor uptake of the conjugate. Anticancer Drugs (1999) 0.86
A 2 m inelastic X-ray scattering spectrometer at CMC-XOR, Advanced Photon Source. J Synchrotron Radiat (2007) 0.86
Methotrexate (MTX) and albumin coupled with MTX (MTX-HSA) suppress synovial fibroblast invasion and cartilage degradation in vivo. Ann Rheum Dis (2004) 0.86
Transverse acoustic excitations in liquid Ga. Phys Rev Lett (2009) 0.84
Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX. Rheumatology (Oxford) (2004) 0.84
[Recurrent meningitis in familial deficiency of the 8th component of the complement system]. Klin Wochenschr (1987) 0.83
Ventricular function in cirrhosis and portasystemic shunt: a two-dimensional echocardiographic study. Hepatology (1988) 0.83
Tissue factor pathway inhibitor: proposed heparin recognition region. Blood Coagul Fibrinolysis (1995) 0.83
Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis. Haemostasis (1990) 0.83
[Clinical features of disseminated intravascular coagulation]. Dtsch Med Wochenschr (1971) 0.83
Magnetic resonance imaging of nude mice with heterotransplanted high-grade squamous cell carcinomas: use of a low-loaded, covalently bound Gd-Hsa conjugate as contrast agent with high tumor affinity. Invest Radiol (2002) 0.83
[New methods in nuclear medicine for placenta localization]. Geburtshilfe Frauenheilkd (1970) 0.82
Laser-induced fluorescence detection of malignant gliomas using fluorescein-labeled serum albumin: experimental and preliminary clinical results. Neurol Res (2000) 0.82
Increase in platelet count in response to rHuEpo in a patient with thrombocytopenia and absent radii syndrome. Blood (2001) 0.82
Multistep tumor targeting in nude mice using bispecific antibodies and a gallium chelate suitable for immunoscintigraphy with positron emission tomography. Cancer Res (1995) 0.82
Fibrin formation and proteolysis during ancrod treatment. Evidence for des-A-profibrin formation and thrombin independent factor XIII activity. Ann N Y Acad Sci (2001) 0.82
Evidence in liver for a disulphide-linked scavenger receptor containing a binding site for acetylated low-density lipoprotein and maleylated bovine serum albumin. Biochem J (1988) 0.81
Scavenging of lipid peroxidation products from oxidizing LDL by albumin alters the plasma half-life of a fraction of oxidized LDL particles. Free Radic Res Commun (1992) 0.81
Investigations concerning the potential for using 1H NMR relaxometry or high-resolution spectroscopy of plasma as a screening test for malignant lung disease. Magn Reson Med (1990) 0.81
Impaired fibrinolytic capacity and tissue plasminogen activator release in patients with restenosis after percutaneous transluminal coronary angioplasty (PTCA). Thromb Haemost (1989) 0.81
Laser-induced fluorescence diagnosis and photodynamic therapy of human renal cell carcinoma. Urol Int (1995) 0.81
Detection of thrombin-induced fibrinogen derivatives in thrombotic states. Bibl Haematol (1977) 0.81
Differentiation of binding sites on reconstituted hepatic scavenger receptors using oxidized low-density lipoprotein. Biochem J (1992) 0.81
Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay. Nephrol Dial Transplant (1995) 0.81
Continuous measurement of hemodynamic alterations during pharmacologic cardiovascular stress using automated impedance cardiography. J Clin Pharmacol (1997) 0.81
Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin. Gynecol Obstet Invest (2000) 0.80
Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats. Anticancer Drugs (1997) 0.80
The influence of hirudin on plasma fibrinogen assays. Thromb Haemost (1998) 0.80
Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol (1999) 0.80
Detection of patients with restenosis after PTCA by dipyridamole-atropine-stress-echocardiography. Int J Card Imaging (1997) 0.79
A new therapeutic option by subcutaneous recombinant hirudin in patients with heparin-induced thrombocytopenia type II: a pilot study. Thromb Res (2000) 0.79
Studies on chemically modified fibrinogen. II. Physicochemical properties of maleylated fibrinogen. Thromb Res (1976) 0.79
Enhanced albumin uptake by rat tumors. Int J Oncol (1997) 0.79
Studies of erythrocyte sequestration. II. Liver homing. Virchows Arch B Cell Pathol (1978) 0.79
Pharmacokinetic properties of LMW-heparin-tyramine fractions with high or low affinity to antithrombin III in the rat. Semin Thromb Hemost (1997) 0.79
The effect of self-monitoring the INR on quality of anticoagulation and quality of life. Semin Thromb Hemost (1999) 0.79